{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ruxolitinib&page=2", "query": { "intervention": "Ruxolitinib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ruxolitinib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T00:54:59.004Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01251965", "title": "Phase l/II Study of Ruxolitinib for Acute Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 27, "start_date": "2010-12", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-09-30T00:54:59.004Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01251965" }, { "nct_id": "NCT04908280", "title": "Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Discoid Lupus Erythematosus" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-05-04", "completion_date": "2024-03-04", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-09-30T00:54:59.004Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04908280" }, { "nct_id": "NCT07424222", "title": "Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 16, "start_date": "2026-07-15", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-30T00:54:59.004Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07424222" }, { "nct_id": "NCT07357727", "title": "A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis (PMF)", "Post-polycythemia Vera Myelofibrosis (PPV-MF)", "Post-essential Thrombocythemia Myelofibrosis (PET-MF)" ], "interventions": [ { "name": "Pelabresib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2026-05-27", "completion_date": "2030-12-27", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-09-30T00:54:59.004Z", "location_count": 15, "location_summary": "New Haven, Connecticut • Fort Myers, Florida • Jupiter, Florida + 12 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07357727" }, { "nct_id": "NCT07278856", "title": "Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Helper T-Cell Lymphoma", "Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type", "Follicular Helper T-Cell Lymphoma, Follicular-Type", "Follicular Helper T-Cell Lymphoma, Not Otherwise Specified", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Peripheral T-Cell Lymphoma, Not Otherwise Specified" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-12-16", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-30T00:54:59.004Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07278856" }, { "nct_id": "NCT05593432", "title": "A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Lichen Planus" ], "interventions": [ { "name": "Ruxolitinib cream", "type": "DRUG" }, { "name": "Vehicle cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2022-11-23", "completion_date": "2024-02-26", "has_results": true, "last_update_posted_date": "2024-10-24", "last_synced_at": "2026-09-30T00:54:59.004Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Skokie", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05593432" }, { "nct_id": "NCT04543279", "title": "Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis", "Thrombocytopenia" ], "interventions": [ { "name": "Fostamatinib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-05-03", "completion_date": "2022-07-30", "has_results": true, "last_update_posted_date": "2023-12-15", "last_synced_at": "2026-09-30T00:54:59.004Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04543279" }, { "nct_id": "NCT03012230", "title": "Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm in the Bone", "Stage IV Breast Cancer AJCC v6 and v7", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-12-06", "completion_date": "2023-03-08", "has_results": false, "last_update_posted_date": "2024-01-31", "last_synced_at": "2026-09-30T00:54:59.004Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012230" }, { "nct_id": "NCT03117751", "title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Erwinase®", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Asparaginase Erwinia chrysanthemi (recombinant)-rywn", "type": "DRUG" }, { "name": "Calaspargase Pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 790, "start_date": "2017-03-29", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-30T00:54:59.004Z", "location_count": 7, "location_summary": "Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03117751" }, { "nct_id": "NCT04041050", "title": "A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Navitoclax", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2019-11-08", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-09-30T00:54:59.004Z", "location_count": 12, "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04041050" } ] }